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Results

Cancer metabolism
▪ In cancer cells, glutaminolysis is the primary source of biosynthetic
precursors, fueling the TCA cycle with glutamine-derived α-ketoglutarate.
▪ α-ketoglutarate provides carbons for the citric acid cycle to produce
glutathione, fatty acids, and nucleotides.
▪ It also contributes nitrogen to produce hexosamines, nucleotides, and many
nonessential amino acids.
▪ Efforts to inhibit glutamine metabolism in cancer using amino acid analogs
have been extensive.

Inhibition of cell growth

Results
Inhibition of cell growth

Necrosis Study

Glutamine analogues

L-γ-methyleneglutamate
▪ L-γ-Methyleneglutamine (1) were first isolated from groundnut seedling
(Arachis hypogaea) in 1952.
▪ It plays a major role in nitrogen transport in Arachis and Amorpha plants.
▪ The syntheses of racemic mixture of 1 were reported in 1955. However, no
efficient synthetic route was reported before our work.

General Synthetic scheme

Discussion
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Study on brain cancer

Study on head and neck cancer

Current work
▪ We will assay the anticancer activity of protected L-γ-Methyleneglutamine
analogues against MCF-7, SK-BR-3, MDA-MB-231 cell lines.
▪ For most potent compound 5, we will do the PK/PD study.
▪ We will also investigate the anticancer activity of both metabolite and
protected metabolites of L-γ-Methyleneglutamine analogues.
▪ For selected compounds from 1-10, we will study anticancer activity
against brain, and head and neck cancer.

Protected L-γ-methyleneglutamate analogues & metabolites

L-γ-methyleneglutamate analogues

Liver concentration versus time profile

Brain concentration versus time profile

concentration (uM)

▪ Amides with primary amine or aromatic amine are more potent in inhibiting
the cancer cells growth than with secondary amine or branched alkyl
amine.
▪ Within each subset, the amines with a stronger electron withdrawing group
exhibit better potency.
▪ N-benzyl amides with an electron withdrawing group at the para position
were the only compounds to inhibit the growth of triple-negative MDA-MB231 cells commensurate to olaparib.

PK study of compound 5
concentration (uM)

▪ There are a number of naturally occurring glutamine analogues, such as
azaserine, acivicin, and 6-diazo-5-oxo-L-norleucine (DON).
▪ These inhibit different glutamine- dependent enzymes including
glutaminase, NAD synthase, CTP synthetase, FGAR aminotransferase.
▪ Therefore, they demonstrated variable degrees of gastrointestinal toxicity,
myelosuppression, and neurotoxicity, due to their non-selectivity.

Discussion
▪ Compare to compound 5 and 6, protected L-γ-methyleneglutamate
analogues, compound 11-30 did not show promising activity in MCF-7, SKBR-3, MDA-MB-231 cell lines.
▪ Both metabolites and protected metabolites, compound 31-35 also did not
show promising activity. However, compound 33 showed better activity in
MDA-MB-231 than others.
▪ PK study showed the good distribution of compound 5 in brain after 30
minutes.
▪ Study of compound 1,4-9 in brain, and head and neck cancer cell lines
showed the concentration dependent inhibition of cell growth of these
cancer cells.

Conclusion & Future Plan
▪ Compound 5 and 6, compare to other analougues showed most potent in
different cancer cell lines whereas, every analogues is non toxic to MCF-10.
▪ We will do further study in zebra fish animal model to investigate binding
target.
• We will also assay these two compounds in different mitochondrial targets.
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